Idiopathic pulmonary sits at the center of this dementia and brain health question.
Pirfenidone, sold under the brand name Esbriet, is the drug most clearly shown to add years to the lives of people with idiopathic pulmonary fibrosis. Studies estimate that pirfenidone extends life expectancy by approximately 2.47 years compared to best supportive care alone — raising mean survival from 6.24 years to 8.72 years. That may sound modest until you consider the baseline: before antifibrotic drugs existed, the average person diagnosed with IPF survived just two to five years. For a disease with no cure, reclaiming roughly a quarter of the years that would otherwise be lost is a significant gain. But pirfenidone is not the only option, and the treatment landscape has shifted considerably.
Nintedanib (Ofev), approved alongside pirfenidone in 2014, shows similar long-term efficacy and may actually edge out pirfenidone in certain patient populations. And in October 2025, the FDA approved nerandomilast (Jascayd) — the first new IPF drug in over a decade — which slows lung function decline even when added on top of existing antifibrotic therapy. This article covers how each of these drugs works, what the survival data actually shows, who benefits most from which treatment, and what the emerging pipeline holds for people living with IPF in 2026. For families already navigating cognitive decline or dementia in a loved one, understanding IPF treatment matters more than you might expect. Chronic lung disease and brain health are deeply intertwined — reduced oxygen delivery accelerates cognitive deterioration, and the breathlessness and fatigue of IPF can mimic or worsen symptoms of dementia. Knowing what treatments are available, and what they can realistically achieve, helps caregivers and patients make informed decisions during an already overwhelming time.
Table of Contents
- Which Drug for Idiopathic Pulmonary Fibrosis Actually Adds Years to Life?
- How Pirfenidone and Nintedanib Compare in Practice
- Nerandomilast — The First New IPF Drug in Over a Decade
- What IPF Treatment Means for Brain Health and Dementia Caregiving
- Limitations of Current IPF Treatments That Families Should Know
- Lung Transplantation as the Only Definitive Life-Extending Treatment
- The IPF Drug Pipeline and What 2026 May Bring
- Conclusion
- Frequently Asked Questions
Which Drug for Idiopathic Pulmonary Fibrosis Actually Adds Years to Life?
The short answer is that both FDA-approved antifibrotic drugs — pirfenidone and nintedanib — extend survival, but pirfenidone has the most direct evidence of adding measurable years. A study published in PMC found that pirfenidone reduced IPF-related mortality by 60 percent and all-cause mortality by 37 percent compared to placebo. Patients taking antifibrotics were 23 percent less likely to die from any cause within the first two years of treatment. In real-world data, mean survival with antifibrotic treatment rose to approximately 58.2 months, compared to 39.9 months for untreated patients — a difference of roughly a year and a half in absolute terms. Nintedanib tells a similar but slightly different story. In some comparative studies, all-cause mortality was 11 percent lower in nintedanib patients than in pirfenidone patients, with a hazard ratio of 0.891.
However, this finding comes with important caveats. Nintedanib appears to show lower mortality in patients with milder disease, while pirfenidone may prolong survival more in those with severe disease. The practical implication is that the “best” drug depends partly on how advanced the fibrosis is at diagnosis, which is something most patients and families are not told upfront. Neither drug cures IPF or reverses scarring that has already occurred. They slow the rate at which the lungs lose function, which in turn delays respiratory failure and death. Lung transplantation remains the only treatment shown to definitively increase life expectancy. But for the many patients who are not transplant candidates — due to age, comorbidities, or personal choice — antifibrotic therapy represents the most effective way to buy time.
How Pirfenidone and Nintedanib Compare in Practice
Choosing between pirfenidone and nintedanib is rarely straightforward, and doctors often base the decision on side effect profiles and individual patient tolerance rather than efficacy alone. Pirfenidone commonly causes photosensitivity and gastrointestinal upset, which can be especially difficult for older adults who spend time outdoors or already have fragile appetites. Nintedanib’s most notable side effect is diarrhea, which in clinical trials affected a significant proportion of patients. For someone already dealing with the physical toll of a chronic lung disease — or managing a second condition like dementia — these side effects are not trivial. They can affect nutrition, hydration, and quality of life in ways that undermine the survival benefit the drug provides. Real-world studies suggest the two drugs perform comparably over time, and switching from one to the other is common when side effects become unmanageable.
However, if a patient has more advanced disease with rapidly declining lung function, the data leans slightly toward pirfenidone’s benefit in that population. Conversely, for patients diagnosed earlier with relatively preserved lung capacity, nintedanib may offer a marginal survival advantage. The important caveat here is that IPF progresses unpredictably — some patients decline slowly over many years, while others experience acute exacerbations that dramatically shorten survival regardless of which drug they take. One limitation that families should understand is that these drugs were studied primarily in patients with mild-to-moderate IPF. The evidence for starting antifibrotic therapy in very advanced disease is thinner, and the side effect burden may outweigh the benefit for patients who are already severely debilitated. This is a conversation worth having with a pulmonologist, particularly when a patient is also managing cognitive impairment and the medication regimen is already complex.
Nerandomilast — The First New IPF Drug in Over a Decade
On October 7, 2025, the FDA approved nerandomilast (brand name Jascayd), developed by Boehringer Ingelheim. It was the first new drug approved for IPF since pirfenidone and nintedanib both came to market in 2014, and it works through a different mechanism — as a PDE4B inhibitor rather than a traditional antifibrotic. By December 2025, nerandomilast had received a second FDA approval for progressive pulmonary fibrosis, broadening its reach beyond IPF alone. The approval was based on the FIBRONEER-IPF Phase III trial, which enrolled 1,177 patients and was published in the New England Journal of Medicine. At 52 weeks, patients taking nerandomilast 18 mg experienced an FVC decline of 114.7 mL, compared to 183.5 mL in the placebo group — a statistically significant difference of 68.8 mL (P<0.001).
What makes this result particularly meaningful is that 77.7 percent of trial participants were already taking nintedanib or pirfenidone. In other words, nerandomilast provided additional benefit on top of existing therapy, not as a replacement. For patients who are already on an antifibrotic and still declining, this is the first evidence that combination treatment can further slow progression. The most common side effect was diarrhea, affecting 41.3 percent of patients in the 18 mg group compared to 16.0 percent on placebo. Since nintedanib also causes diarrhea, combining the two drugs could make gastrointestinal symptoms especially challenging. This is a practical consideration that families and caregivers need to plan for, particularly when managing medications for someone who also has cognitive difficulties and may not be able to articulate their discomfort clearly.
What IPF Treatment Means for Brain Health and Dementia Caregiving
The connection between lung disease and cognitive decline is better established than most people realize. Chronic hypoxia — the reduced oxygen levels that come with progressive lung scarring — has been linked to accelerated cognitive deterioration, increased risk of vascular dementia, and worsening of existing Alzheimer’s disease symptoms. When a person with IPF is also living with early or moderate dementia, every month of preserved lung function translates to better oxygen delivery to the brain. This is one reason why the 2.47 additional years that pirfenidone provides is not just a respiratory statistic — it has neurological implications as well. From a caregiving standpoint, the practical tradeoffs are real. Adding an antifibrotic medication to an already complex drug regimen requires careful coordination.
Pirfenidone, for example, must be taken three times daily with food, and the photosensitivity it causes demands behavioral changes — wearing sunscreen, avoiding prolonged sun exposure — that a person with dementia may not remember or cooperate with. Nintedanib is taken twice daily, which is simpler, but its gastrointestinal side effects can lead to dehydration and nutritional deficits if not monitored closely. The decision to treat IPF aggressively in a patient with concurrent dementia is deeply personal. Treatment prolongs progression-free survival by about 25 percent and reduces mortality by roughly half after one year — numbers that most families would consider meaningful. But the quality of that additional time matters enormously. A frank conversation with both the pulmonologist and the neurologist, ideally together, is the best way to weigh the benefits of antifibrotic therapy against the burden it places on the patient and the family.
Limitations of Current IPF Treatments That Families Should Know
No currently available drug reverses the scarring that has already occurred in the lungs. This is the single most important limitation of IPF treatment, and it is frequently misunderstood. Antifibrotic drugs slow the rate of decline — they do not restore lost function. A patient who begins treatment with 60 percent of normal lung capacity will not return to 80 percent. The goal is to keep that 60 percent from dropping to 40 percent as quickly as it otherwise would. Acute exacerbations remain a serious and unpredictable threat even for patients on treatment. These sudden episodes of rapid lung function decline carry a mortality rate above 50 percent and are one of the leading causes of death in IPF.
Neither pirfenidone nor nintedanib has been convincingly shown to prevent acute exacerbations, though some data suggests they may reduce the frequency. For caregivers, this means that even with optimal treatment, IPF can take a sudden and devastating turn without warning. Having advance directives in place — especially when dementia complicates decision-making — is not pessimistic planning. It is responsible care. Access and cost are also barriers. Antifibrotic drugs are expensive, often exceeding tens of thousands of dollars per year, and insurance coverage varies. Nerandomilast, as the newest option, may face additional hurdles with payer approval. Patient assistance programs exist through the manufacturers, but navigating them requires time and persistence — resources that are often in short supply for families already managing dual diagnoses of IPF and dementia.
Lung Transplantation as the Only Definitive Life-Extending Treatment
For patients who are eligible, lung transplantation remains the only treatment shown to definitively increase life expectancy in IPF. Antifibrotic drugs buy time; transplantation can fundamentally change the trajectory. However, candidacy requirements are strict — most transplant programs set upper age limits, require adequate nutritional status, and evaluate whether the patient can adhere to a complex post-transplant medication regimen.
A concurrent diagnosis of moderate-to-severe dementia typically disqualifies a patient from consideration, which is a painful reality for many families. Even for eligible patients, the transplant waiting list introduces its own uncertainties. Median wait times vary by blood type, body size, and geographic region, and not every patient survives long enough to receive an organ. This is precisely why antifibrotic therapy is so valuable as a bridge — maintaining lung function for as long as possible improves both quality of life and transplant candidacy during the wait.
The IPF Drug Pipeline and What 2026 May Bring
The approval of nerandomilast in late 2025 signaled that the IPF treatment landscape is finally expanding after a decade of stagnation, and the pipeline holds additional promise. BMS-986278, a lysophosphatidic acid receptor antagonist, is currently in a Phase 3 study with recruitment ongoing and results expected in 2026. Taladegib, which targets the Hedgehog signaling pathway, received Orphan Drug Designation in July 2025, and its Phase 2b WHISTLE-PF trial is expected to complete enrollment in 2026 as well.
These emerging therapies represent fundamentally different approaches to fibrosis — targeting distinct biological pathways rather than iterating on existing mechanisms. If any of them prove effective, the possibility of multi-drug combination regimens for IPF becomes realistic, much as combination therapy transformed outcomes in cancer and HIV. For the millions of families currently managing IPF alongside other chronic conditions, the prospect of slowing disease progression even further is worth watching closely.
Conclusion
Idiopathic pulmonary fibrosis remains an incurable disease, but the notion that nothing can be done is outdated. Pirfenidone adds approximately 2.47 years of life expectancy and reduces IPF-related mortality by 60 percent. Nintedanib provides comparable long-term benefit with a different side effect profile. And nerandomilast, approved in late 2025, offers the first evidence that combination therapy can slow decline beyond what a single antifibrotic achieves alone.
Together, these drugs have shifted IPF from a diagnosis measured in months to one increasingly measured in years. For families managing both IPF and cognitive decline, the stakes are compounded but so are the opportunities. Preserving lung function preserves oxygen delivery to the brain, which matters profoundly for someone with dementia. The decision about which drug to use, when to start, and whether to pursue combination therapy should involve a coordinated medical team and honest conversations about goals of care. No drug can stop IPF entirely — but the right treatment, started at the right time, can meaningfully extend and improve the years that remain.
Frequently Asked Questions
Can pirfenidone or nintedanib cure idiopathic pulmonary fibrosis?
No. Neither drug cures or reverses IPF. Both are antifibrotic medications that slow the rate of lung function decline, which delays progression and extends survival. The lung scarring that has already occurred remains permanent.
How much longer can someone with IPF expect to live with treatment?
Studies show pirfenidone extends mean life expectancy by approximately 2.47 years compared to best supportive care. Real-world data across antifibrotic treatments shows mean survival of about 58.2 months with treatment versus 39.9 months without — an increase of roughly 18 months in absolute terms.
Can nerandomilast be taken alongside pirfenidone or nintedanib?
Yes. In the FIBRONEER-IPF trial, 77.7 percent of patients were already taking either pirfenidone or nintedanib. Nerandomilast showed additional benefit on top of existing antifibrotic therapy. However, overlapping side effects — particularly diarrhea — may require careful management.
Is a person with both IPF and dementia eligible for a lung transplant?
Generally, moderate-to-severe dementia disqualifies a patient from lung transplant candidacy because post-transplant care requires strict medication adherence and frequent follow-up. Patients with very mild cognitive impairment may still be evaluated on a case-by-case basis, but this is a conversation to have early with both the transplant team and the neurologist.
What is the newest drug approved for IPF?
Nerandomilast (brand name Jascayd), a PDE4B inhibitor made by Boehringer Ingelheim, was approved by the FDA on October 7, 2025. It received a second approval in December 2025 for progressive pulmonary fibrosis. It is the first new IPF drug approval in over a decade.
Does IPF treatment affect brain health or slow cognitive decline?
IPF treatment itself does not directly target the brain. However, by preserving lung function and maintaining better blood oxygen levels, antifibrotic therapy may help reduce the cognitive damage caused by chronic hypoxia. This is particularly relevant for patients who also have dementia or are at elevated risk for cognitive decline.
You Might Also Like
- The Cancer Drug Pill Taken Once Daily That Replaced Monthly IV Infusions
- This Muscle Drug Is Given Before Surgery to Prevent Complications
- This Drug Is Changing the Way Hospitals Prevent Blood Clots
For more, see CDC — Alzheimer’s and Dementia.
